Abstract
Aim: Long noncoding RNA (lncRNA) noncoding RNA activated by DNA damage (NORAD) is widely investigated in different tumors. Our meta-analysis intends to assess the prognostic and clinicopathological value of NORAD in cancers. Materials & methods: We searched PubMed, Web of Science, Embase and Chinese National Knowledge Infrastructure from inception to 1 August 2020. Results: The results showed that higher expression of NORAD had a significant association with worse overall survival. Additionally, correlations were detected between elevated level of NORAD and poor differentiation degree, positive lymph node metastasis and large tumor size in cancer patients. Conclusion: LncRNA NORAD can serve as a novel and promising biomarker for prognosis and clinicopathological characteristics in different cancers.
| Original language | English |
|---|---|
| Pages (from-to) | 427-436 |
| Number of pages | 10 |
| Journal | Biomarkers in medicine |
| Volume | 15 |
| Issue number | 6 |
| DOIs | |
| State | Published - Apr 2021 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- NORAD
- clinicopathological features
- meta-analysis
- prognosis
- tumor
Fingerprint
Dive into the research topics of 'Prognostic and clinicopathological role of long noncoding RNA NORAD in various cancers: A meta-analysis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver